Generated by AI
Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.
Website321 Harrison Avenue
Boston, MA, 02118
United States
The latest articles about PYXS.
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027 Company to host a live webcast on November 19, 2026, at 7:00 a.m. EST, foll
Summary of Sep 30's posts. Generated by AI.
Summary of Oct 9's posts. Generated by AI.
Summary of Feb 27's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
Investors talking about PYXS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.